NCT03460223 is a Phase 1, PHASE2 clinical trial of MSC in Renal Cirrhosis, sponsored by Nanjing Medical University.

Who is sponsoring NCT03460223?

NCT03460223 is sponsored by Nanjing Medical University.

What drugs are being tested in NCT03460223?

Interventions in NCT03460223: MSC.

What condition does NCT03460223 study?

NCT03460223 studies Renal Cirrhosis.

Is NCT03460223 still recruiting?

NCT03460223 is currently status unknown. Last updated 9 March 2018.

Last reviewed 2018-03-09 · How we verify

NCT03460223

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy Study of Mesenchymal Stem Cell in Treating Kidney Fibrosis

Status unknown Phase 1, PHASE2 Last updated 9 March 2018

What this trial tests

Phase 1, PHASE2 trial testing MSC in Renal Cirrhosis in 30 participants. Status unknown.

Timeline

1 April 2018

Primary endpoint
1 March 2020

1 September 2020

Quick facts

Lead sponsor	Nanjing Medical University
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 April 2018
Primary completion	1 March 2020
Estimated completion	1 September 2020

Drugs / interventions tested

MSC — full drug profile →

Conditions studied

Renal Cirrhosis — all drugs for Renal Cirrhosis →

Sponsor

Nanjing Medical University

Who can join

Adults 18 to 70, any sex, with Renal Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In progressive kidney diseases, fibrosis represents the common pathway to end-stage kidney failure. The potential for stem cells to treat kidney failure was recently confirmed. Particularly, mesenchymal stem cell (MSC) has been demonstrated to protect kidney function and alleviating renal injury in these patients. Therefore, the investigators propose a hypothesis that MSCs (MSC) can also improve the disease conditions of kidney fibrosis patients, particularly reducing the decompensated conditions in these patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Druggability of lipid metabolism modulation against renal fibrosis.
Chen YY, Chen XG, Zhang S. · · 2022 · cited 43× · PMID 33990764 · DOI 10.1038/s41401-021-00660-1
Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges.
Chen F, Chen N, Xia C, Wang H, et al · · 2023 · cited 30× · PMID 37013255 · DOI 10.1177/09636897231164251

Verify or expand the search:

Other trials of MSC

Trials testing the same drug.

NCT06823063 — Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-P) in the Treatment of CTD-ILD · Phase 1 · not yet recruiting
NCT06813157 — Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia · NA · recruiting
NCT06788470 — Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stem Cell(MSC) Transplantation in the Treatment of Bronchopulm · Phase 1, PHASE2 · recruiting
NCT05697718 — Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke · Phase 1 · completed
NCT04611256 — Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 · Phase 1 · unknown

Other Nanjing Medical University trials

Trials by the same sponsor.

NCT07382375 — AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection · NA · not yet recruiting
NCT07494474 — Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD · not yet recruiting
NCT07482774 — Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma · not yet recruiting
NCT07348328 — Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery · NA · not yet recruiting
NCT07258394 — Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03460223 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing Medical University
Last refreshed: 9 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03460223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing